YDES YD Bio Ltd
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma. It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens, a spherical and aspherical lenses. In addition, the company supplies drugs and medical materials for clinical trials; and operates DNA methylation-based oncology testing programs. Further, it provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination, and compliance-focused support for clinical development programs to pharmaceutical and biotechnology companies. It serves corporate and retail customers. It has a strategic collaboration with EG BioMed Co., Ltd. and JoiiUp to launch AI-driven cancer risk assessment for corporate wellness. The company was founded in 2013 and is based in Taipei, Taiwan.…
Industry Peers
BiotechnologyKey Statistics
About YD Bio (NASDAQ: YDES)
›
YD Bio (NASDAQ: YDES) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 13 employees.
The shares were at 4.560 USD on 19 November 2026, down 53.3% over 52 weeks. Its 52-week range is 1.700 USD to 15.72 USD: the price is 71.0% below the high and 168.2% above the low.
Its market capitalisation is 322.99M USD.
YD Bio reports return on equity of 291.0% and revenue up 314.9% year over year.
It holds more cash than debt, a net cash position of 2.66M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.